CSL Limited, commonly referred to as CSL, is a global biotechnology leader headquartered in Australia. Founded in 1916, the company has evolved significantly, establishing a strong presence in key operational regions including North America, Europe, and Asia-Pacific. Specialising in the development of innovative therapies for rare and serious diseases, CSL focuses on areas such as immunology, haematology, and respiratory health.
The company is renowned for its core products, including immunoglobulins and clotting factors, which are distinguished by their high quality and efficacy. CSL's commitment to research and development has positioned it as a market leader, with notable achievements such as being consistently ranked among the top biopharmaceutical companies globally. With a rich history and a dedication to improving patient outcomes, CSL continues to set benchmarks in the biotechnology industry.
+3 vs industry average
Csl’s score of 41 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Csl?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Csl's reported carbon emissions
In 2025, CSL Limited reported total emissions of approximately 286,000,000 kg CO2e, comprising 135,000,000 kg CO2e from Scope 1 and 151,000,000 kg CO2e from Scope 2. The company has set ambitious climate commitments, aiming for a 40% reduction in absolute Scope 1 and 2 emissions by 2030, using the average annual emissions from fiscal years 2019 to 2021 as a baseline. Additionally, CSL has committed to a 42% reduction in absolute Scope 1 and 2 GHG emissions by FY2030 from a FY2021 base year, as part of its Science Based Targets initiative (SBTi) commitments. CSL's emissions data reflects a consistent focus on sustainability within the pharmaceutical and biotechnology sector, with a commitment to ensuring that 73.1% of its suppliers by emissions will have science-based targets by FY2030. The company continues to enhance its climate strategy, aligning with industry standards to mitigate its environmental impact.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Csl’s Climate Goals (2030 & 2050)
1 goal2030
40% reduction in all scopes
40% reduction by 2030 on baseline (335 kilotonnes of CO₂-e)
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 1 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Csl
Frequently asked questions
Common questions about Csl’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project